Skip to main content

What to Expect From Emerson Electric's Next Quarterly Earnings Report

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Saint Louis, Missouri-based Emerson Electric Co. (EMR) is a technology and software company that provides various solutions. With a market cap of $78.9 billion,  the company offers control systems, sensors, and valves, as well as electrical infrastructure and tools for industrial, commercial, and consumer markets worldwide. The automation giant is expected to announce its fiscal second-quarter earnings for 2026 in the near term.

Ahead of the event, analysts expect EMR to report a profit of $1.55 per share on a diluted basis, up 4.7% from $1.48 per share in the year-ago quarter. The company has surpassed or met Wall Street’s EPS estimates in its last four quarterly reports. 

 

For the full year, analysts expect EMR to report EPS of $6.51, up 8.5% from $6 in fiscal 2025. Its EPS is expected to rise 9.5% year over year to $7.13 in fiscal 2027. 

www.barchart.com

EMR stock has outperformed the S&P 500 Index’s ($SPX) 33.5% gains over the past 52 weeks, with shares up 42.3% during this period. Similarly, it outperformed the State Street Industrial Select Sector SPDR ETF’s (XLI36.7% gains over the same time frame.

www.barchart.com

EMR's outperformance was driven by broad-based demand for automation in North America, India, and the Middle East, with strength in power, LNG, and test & measurement. AI-enabled products like Nigel.ai and DeltaV, plus a $7.9 billion backlog and 70 major project wins, fueled profitability. Management raised guidance on long-cycle projects, AI software growth, and backlog conversion, despite softness in Europe and China.

Analysts’ consensus opinion on EMR stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 25 analysts covering the stock, 13 advise a “Strong Buy” rating, one suggests a “Moderate Buy,” 10 give a “Hold,” and one recommends a “Moderate Sell.” EMR’s average analyst price target is $165.12, indicating a potential upside of 17.6% from the current levels.


On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  250.56
+0.86 (0.34%)
AAPL  270.23
+6.83 (2.59%)
AMD  278.39
+0.13 (0.05%)
BAC  53.91
+0.40 (0.75%)
GOOG  339.40
+6.63 (1.99%)
META  688.55
+11.68 (1.73%)
MSFT  422.79
+2.53 (0.60%)
NVDA  201.68
+3.33 (1.68%)
ORCL  175.06
-3.28 (-1.84%)
TSLA  400.62
+11.72 (3.01%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.